-
Intraday Gainers; Luminex up Over 25%
Tuesday, August 9, 2011 - 3:08pm | 96Luminex Corporation (NASDAQ: LMNX) +25.49% after reporting upbeat yesterday and having its PT raised by Jefferies and Piper Jaffray Walter Investment Management (NYSE: WAC) +16.41 after reporting its Q2 earnings. Universal Display Corporation (NASDAQ: PANL) +14.04% on upbeat earnings. MEMC...
-
WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting
Tuesday, August 9, 2011 - 11:30am | 32WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced shareholder resolutions adopted at its annual general meeting of shareholders held in Hong Kong on August 9, 2011.
-
Thermo Fisher Scientific Announces Offering of Senior Notes
Tuesday, August 9, 2011 - 10:33am | 55Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that it intends to offer senior notes to fund, in part, its acquisition of Phadia. The aggregate purchase price of this transaction is estimated to be €2.47 billion (approximately $3.5 billion). The Phadia acquisition was announced by the...
-
UPDATE: Ladenburg Thalmann Downgrades Response Genetics to Neutral, Removes PT
Tuesday, August 9, 2011 - 8:51am | 49Ladenburg Thalmann downgraded its rating on Response Genetics (NASDAQ: RGDX) from Buy to Neutral. At the same time, the rating agency removed its price target on the company's stock. Its previous price target was $3.50. On Monday, RGDX closed the day at $2.49.
-
Ladenburg Thalmann Downgrades Response Genetics To Neutral, Removes PT
Tuesday, August 9, 2011 - 8:29am | 26Ladenburg Thalmann has downgraded Response Genetics (NASDAQ: RGDX) from Buy to Neutral and has removed its $3.50 price target.
-
UPDATE: Jefferies Lowers PT on Charles River Laboratories to $33
Tuesday, August 9, 2011 - 7:31am | 93Jefferies is out with its report today on Charles River Laboratories (NYSE: CRL), lowering its PT from $40 to $33. In its report, Jefferies writes, "We are lowering our PT to $33, or 12.5x our 2012 EPS estimate of $2.65. This is an overly steep reduction under normal circumstances. However, to...
-
UPDATE: Jefferies Raising Price Target On Luminex Corp
Tuesday, August 9, 2011 - 7:29am | 96Jefferies & Co. is out with a research report on Luminex Corp (NASDAQ: LMNX) and is raising its price target to $18 from $17, and it has a Hold rating on shares. In a note to clients, Jefferies & Co. writes, "LMNX's 2Q11 non-GAAP EPS of $0.14 was $0.08 ahead of consensus on vastly stronger...
-
UPDATES: Piper Jaffray Reiterates Underweight on Luminex, Raises PT to $19
Tuesday, August 9, 2011 - 7:15am | 47Piper Jaffray reiterated its Underweight rating on Luminex (NASDAQ: LMNX). At the same time, the rating agency raised its price target on the company's stock from $17 to $19. On Monday, LMNX lost 6% of its value to finish the day at $18.50.
-
Jefferies Raises PT On Luminex To $18
Tuesday, August 9, 2011 - 7:00am | 26Jefferies & Company has raised the price target on Luminex (NASDAQ: LMNX) from $17 to $18 and maintains its Hold rating.
-
Jefferies Lowers PT On Charles River Laboratories To $33
Tuesday, August 9, 2011 - 6:26am | 28Jefferies & Company has lowered the price target on Charles River Laboratories (NYSE: CRL) from $40 to $33 and maintains its Hold rating.
-
Piper Jaffray Raises PT On Luminex To $19
Tuesday, August 9, 2011 - 6:20am | 26Piper Jaffray has raised the price target on Luminex (NASDAQ: LMNX) from $17 to $19 and maintains its Underweight rating.
-
Caliper and Carestream Settle Lawsuits
Monday, August 8, 2011 - 8:15am | 157Caliper Life Sciences, Inc. (NASDAQ: CALP) today announced that it has favorably settled two lawsuits with Carestream Health, Inc. In the first lawsuit, filed in February 2010, Caliper, its wholly owned subsidiary, Xenogen, and Stanford University alleged that Carestream's marketing and sales of...
-
A Peek Into The Market Before The Trading Starts
Monday, August 8, 2011 - 7:27am | 378Pre-open movers US stock futures are lower this morning, after Standard & Poor's downgraded the US debt rating. Futures for the Dow Jones Industrial Average dipped 222 points to 11,180.00 and S&P 500 index futures fell 27.80 points to 1,170.00. Nasdaq 100 futures dropped 51.75 points to 2,...
-
UPDATE: Deutsche Bank Lowers PT on Nektar Therapeutics to $11
Monday, August 8, 2011 - 7:22am | 78Deutsche Bank is out with its report today on Nektar Therapeutics (NASDAQ: NKTR), lowering its PT from $14 to $11. In its report, Deutsche Bank writes, "Reflecting recent multiple compression in the sector, we are reducing our 12 month price target to $11 (from $14), based on 20x (vs 25x...
-
Affymetrix Commercializes Next-Generation Transcriptome Array for Large-Scale Clinical Studies
Monday, August 8, 2011 - 6:45am | 89Affymetrix, Inc. (NASDAQ: AFFX) today announced commercialization of the next-generation human transcriptome array demonstrated by Stanford University researchers to be superior to mRNA sequencing in gene expression profiling studies. In multiple experiments using a clinically relevant...